Caplin Point Laboratories Limited

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018, received from Integrated Registry Management Services Private Limited, the Registrar and Transfer Agent of the Company, for the quarter and half year ended September 30, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015, in connection with the finalization of unaudited Financial Results for the quarter and half year ending September 30, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has submitted the Exchange a copy Scrutinizers report of Annual General Meeting held on September 25, 2026, and informed the Exchange regarding voting results.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited held its 35th Annual General Meeting on September 25, 2026, through video conferencing. The meeting was attended by the directors, except Mr. Ashok Partheeban, and the company secretary. The chairman presented the performance of the company, and the managing director delivered a speech on the company's performance. The meeting concluded with a vote of thanks and the results of remote e-voting/e-voting to be announced within 2 working days.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has responded to a National Stock Exchange of India Limited email regarding a significant increase in trading volume of its shares, stating that the increase is market-driven and that the company has made all requisite disclosures.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has seen a significant increase in trading volume, prompting the exchange to seek clarification from the company.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange about Copy of Newspaper Publication regarding the notice of the 35th Annual General Meeting of the Company, to be held through Video Conferencing/Other Audio-Visual Means on September 25, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange regarding 'Letter to Shareholders' for the 35th Annual General Meeting and Annual Report for the financial year 2025-26.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has submitted its Business Responsibility and Sustainability Report (BRSR) for the Financial Year 2025-26, as per Regulation 34(2)(f) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange regarding Notice of Annual General Meeting to be held on September 25, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has responded to a query from the National Stock Exchange regarding a significant increase in trading volume of its shares, stating that the increase is market-driven and that it has made all requisite disclosures.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange about a newspaper advertisement for the 35th Annual General Meeting, scheduled to be held on September 25, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange regarding 'Receipt of Good Manufacturing Practices (GMP) Compliance Certification by Caplin One Labs Limited (COL), a subsidiary company, from INVIMA'.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has seen a significant increase in trading volume, prompting the NSE to write to the company for clarification. The company's response is pending.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange regarding 'Completion of Unannounced US FDA Inspection at the facility of Caplin Steriles Limited (Company's Subsidiary)'

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange about the transcript of the earnings call for Q1 FY 2026-27, available on the company's website.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange about the link of the recording of the earnings call for Q1 FY 2026-27, which was held on August 12, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange about Investor Presentation and announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The company has also recommended a Final Dividend of Rs.4/- (200%) per equity share of Rs.2/- each for the financial year ended March 31, 2026.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has informed the Exchange regarding Change in Director(s) of the company. The company has re-appointed Dr. Sridhar Ganesan as the Managing Director for a further period of two years and appointed Mr. D. Muralidharan as the Whole-Time Director for a period of two years, subject to the approval of Shareholders at the ensuing AGM.

Caplin Point Laboratories Limited

Caplin Point Laboratories Limited has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, and has recommended a final dividend of Rs. 4 per equity share for the financial year ended March 31, 2026.